Acute Coronary Syndrome
Conditions
Interventions
Ezetimibe 10mg daily Atorvastatin 10mg daily
Sponsors
Department of Cardiovascular Medicine, Juntendo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The ethical committee of all participation center approved the protocol and all patients provided written informed consent.This study will be included men and women>=20 years of age with clinical diagnosis of acute coronary syndrome (ACS) who will meet IVUS criteria
Exclusion criteria
Exclusion criteria: 1,Advanced liver dysfunction 2,Renal failure 3,LDL cholesterol Level<100mg/dl 4,Any other reason for exclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the percent change in coronary plaque volume | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) absolute change from baseline in coronary plaque volume, (2) absolute change from baseline in coronary plaque stabilization(3)absolute and percent change in serum lipid and apolipoproteins (4) percent change in cholesterol absorption and synthesis markers (5)Correlation oflipid parameters and percent change in coronary plaque volume/stabilization (6) percent change in inflammatory marker and white blood cell count, (7) absolute and percent change in the coronary plaque area at the site of PCI, (8) absolute and percent change in MLD and %stenosis at the site of PCI, (9) major adverse cardiovascular event (MACE: defined as cardiac death, Q or non-Q wave myocardial infarction or TVR), (10) death, (11) any adverse incidents including changes in laboratory values | — |
Countries
Japan
Contacts
Public ContactKatsumi Miyauchi
Juntendo University School of Medicine Department of Cardiovascular Medicine
Outcome results
None listed